

Since this is a very extensive table, the format and content has not been edited by ActaDV.

Table I. *Characteristics of included studies*

Reference	Study design	Inclusion criteria	DM <i>n</i>	Length of follow-up	Auto-antibodies determined	Method of autoantibody determination	Positive for anti- TIF-1 auto- antibody tested, <i>n</i>	Positive for anti-TIF-1 auto- antibody who had CAD, <i>n</i>	Definition of CAD	Patients with CAD, <i>n</i>
Targoff et al., 2006 (13), USA	Retrospective cohort study	Adult patients (age $\geq 18$ years) diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) criteria, included between 1997 and 2000	45	Not specified	Anti-p155 or anti-p155/140	IP assays using leukaemia cell line K562 or HeLa cells	14	6	CAD, defined according to the Love et al. (49) classification	6
Chinoy et al., 2007 (17), UK	Retrospective cohort study	Adult patients (age $\geq 18$ years) diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) criteria, included between 1999 and 2004	103	Mean 3 years (>90% followed up for >3 years)	Anti-p155/140	IP assays using leukaemia cell line K562	19	8	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	15
Kaji et al., 2007 (16), Japan	Retrospective cohort study	Patients (age ranging from 13 to 84 years, mean age: 55 years) diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, inclusion dates not specified	52	$\geq 2$ years for 30 patients	Anti-p155/140	IP assays using leukaemia cell line K562	7	5	Malignancies (CAD criteria not defined, but all cancers diagnosed <3 years within DM diagnosis)	10
Gunawardena et al., 2008 (18), UK	Prospective cohort study	Adult patients diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) criteria, inclusion dates not specified	20	Not specified	Anti-p155/140	IP assays using leukaemia cell line K562	6	3	Malignancies (CAD criteria not defined but all neoplasms diagnosed either at onset or within 3 months of their presentation of classic DM)	3
Hoshino et al., 2010 (22), Japan	Retrospective cohort study	Patients (between 3 and 84 years, mean age: 50 years) diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, inclusion dates not specified	74	Not specified	Anti-p155	IP assays using HeLa cells	12	7	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	12
Kang et al., 2010 (21), Korea	Retrospective cohort study	Adult patients (age >18 years) diagnosed as having definite DM using Bohan & Peter's (37, 38) criteria, included between 1993 and 2007	38	4.92 $\pm$ 4.32 years after diagnosis of DM	Anti-p155	IP assays using HeLa cells	8	5	CAM, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	9
Trallero-Araguas et al., 2010 (20), Spain	Prospective cohort study	Adult patients diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 1983	65	Median 4 years (IQR 1.9–7.2) (>77% followed up for >3 years)	Anti-p155	IP assays using HeLa cells	15	10	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified	14

									and 2007	
Ikeda et al., 2011 (25), Japan	Retrospective cohort study	Adult patients diagnosed as having definite DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2000 and 2009	55	Not specified	Anti-p155 or anti-p155/140	IP assays using leukaemia cell line K562 or HeLa cells	9	4	Bohan & Peter's classification CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	18
Hamaguchi et al., 2011 (24), Japan	Retrospective cohort study	Adult patients diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2003 and 2008	376	Not specified but in patients with anti-p155/140 mean 1.8 and 3.5 years for patients with and without cancer	Anti-p155/140	IP assays using leukaemia cell line K562	25	17	CAD, defined according to the Love et al. (49) classification	39
Labrador-Horillo et al., 2012 (26), Spain	Retrospective cohort study	Adult patients diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 1983 and 2011	90	Not specified	Anti-p155	IP assays using HeLa cells + Immunoblot and ELISA	24	13	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	19
Fiorentino et al., 2013 (27), USA	Retrospective cohort study	Adult patients (age >18 years) diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2003 and 2012	213	Mean 4.1 years (>71% followed up >3 years)	Anti-p155	IP assays using HeLa cells	82	15	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	29
Fiorentino et al., 2015 (28), USA	Retrospective cohort study	Adult patients (age >18 years) diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2004 and 2013	122	Mean 5.3 years	Anti-p155	IP assays using HeLa cells	46	10	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	18
Bernet et al., 2016 (33), USA	Prospective cohort study	Patients (median age >55 years) diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2014 and 2015	45	Not specified	Anti-p155	Not specified	23	6	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	8
Fujimoto et al., 2016 (32), Japan	Retrospective cohort study	Adult patients diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2011 and 2014	172	Not specified	Anti-p155 or anti-p155/140	IP assays using leukaemia cell line K562 or ELISA or IB	34	23	CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified	35

Hida et al., 2016 (29), Japan	Retrospective cohort study	Adult patients (>16 years) diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2000 and 2013	143	Mean 3.2 years±57 days	Anti-p155	IP assays using HeLa cells	39	34	Bohan & Peter's classification CAD, defined according to temporal criteria proposed by Troyanov et al. (48) in their modified Bohan & Peter's classification	41
Mugii et al., 2016 (31), Japan	Retrospective cohort study	Adult patients diagnosed as having DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2004 and 2015	92	Not specified	Anti-p155/140	IP assays using leukaemia cell line K562	26	13	Not specified	19
Best et al., 2017 (34), France	Prospective cohort study	Adult patients (age >18 years) diagnosed as having DM using Bohan & Peter's (37, 38) or Gerami's (40) criteria, included between 2013 and 2015	97	>2 years	Anti-p155 or anti-p155/140	Immunodot	13	6	CAD, defined if cancer diagnosed 1 year preceding or 2 years after the beginning of DM symptoms	27
Ogawa-Momohara et al., 2018 (35), Japan	Retrospective cohort study	Adult patients diagnosed as having definite or probable DM using Bohan & Peter's (37, 38) or Sontheimer's (39) criteria, included between 2003 and 2016	160	Mean 3 years±38.7 months	Anti p155	ELISA	34	23	Not specified	41

CAD: cancer-associated dermatomyositis; DM: dermatomyositis; ELISA: enzyme-linked immunosorbent assay; IQR: interquartile range; IP: immunoprecipitation; SD: standard deviation.